Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.

Abstract

AIM:

To analyze the efficacy of last line sorafenib treatment in colorectal cancer patients.

METHODS:

All patients receiving chemotherapy for colorectal cancer in the outpatient clinic of the University of Mainz since 2006 were retrospectively analyzed for last line sorafenib exposure. Charts of identified patients were analyzed for clinic-pathological parameters, like data on gender, age, date of initial diagnosis, UICC stage, number and kind of the pre-therapies, therapy start and end of sorafenib, sorafenib mediated treatment cessation, side effects, response rates, time to progression and overall survival.

RESULTS:

Ten patients with a median of 3.0 prior chemotherapy lines had received a last line sorafenib therapy either alone (10%) or in combination with 5-fluorouracil derivates (90%). All patients suffered from colorectal cancer stage UICC 4 and were routinely seen in 2-wk intervals in the oncology outpatient clinic. Median duration of treatment was 142.0 d. At 8 wk 80% of patients showed stable disease but we did not observe any remissions. Median time to progression was 140.5 d (4.7 mo), while median overall survival reached 176.5 d. One patient ceased treatment due to side effects. Reason for treatment stop was bleeding complication in one case and non-specified sorafenib intolerance in another case. Due to the retrospective approach we did not further quantify side effects.

CONCLUSION:

This retrospective analysis encourages further investigation of sorafenib in colorectal cancer last line therapy.

• Authors: Ksenia Martchenko, Irene Schmidtmann, Thomas Thomaidis, Verena Thole, Peter R Galle, Marc Becker, Markus Möhler, Thomas C Wehler, Carl C Schimanski
• Journal: World journal of gastroenterology (World J Gastroenterol) Vol. 22 Issue 23 Pg. 5400-5 (Jun 21 2016) ISSN: 2219-2840 [Electronic] United States
• PMID: 27340356 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Phenylurea Compounds
• Niacinamide
• Sorafenib
• Receptor Protein-Tyrosine Kinases
• Fluorouracil

Topics

• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Colorectal Neoplasms (drug therapy, mortality, pathology)
• Disease-Free Survival
• Female
• Fluorouracil (analogs & derivatives)
• Humans
• Male
• Neoplasm Staging
• Niacinamide (adverse effects, analogs & derivatives, therapeutic use)
• Off-Label Use
• Phenylurea Compounds (adverse effects, therapeutic use)
• Receptor Protein-Tyrosine Kinases (antagonists & inhibitors)
• Retrospective Studies
• Sorafenib
• Withholding Treatment